Wilson Disease

What is Wilson Disease?

Wilson Disease (ORPHA:905) is a rare genetic disorder that causes copper to accumulate in the liver, brain, and other organs due to the body’s inability to properly eliminate excess copper. This autosomal recessive condition affects approximately 1 in 30,000 to 1 in 100,000 people worldwide, with symptoms typically appearing between ages 5 and 35. Without treatment, Wilson Disease can be fatal, but early diagnosis and appropriate therapy can prevent serious complications and allow patients to live normal lives. The disease equally affects males and females and occurs in all ethnic groups, though certain populations show higher carrier frequencies.

Key statistics

Symptoms

Common symptoms include: liver dysfunction, neurological problems, psychiatric symptoms, kidney stones, arthritis, Kayser-Fleischer rings in the eyes, fatigue, and abdominal pain.

Wilson Disease presents with three main categories of symptoms. Hepatic symptoms often appear first and include fatigue, abdominal pain, jaundice, nausea, vomiting, loss of appetite, and fluid accumulation in the abdomen. Some patients develop acute liver failure or chronic liver disease resembling autoimmune hepatitis or cirrhosis. Neurological symptoms typically emerge in the teens or twenties and include tremors, difficulty with coordination and balance, slurred speech, difficulty swallowing, muscle stiffness, and involuntary movements. Psychiatric symptoms can include depression, anxiety, personality changes, behavioral problems, psychosis, and cognitive difficulties.

Additional symptoms may include Kayser-Fleischer rings (copper deposits forming golden-brown rings around the cornea), kidney stones, arthritis, osteoporosis, heart rhythm abnormalities, and menstrual irregularities in women. Early symptoms are often subtle and non-specific, leading to delayed diagnosis.

Submit Your Paper

Causes and risk factors

Wilson Disease is caused by mutations in the ATP7B gene, which provides instructions for making a protein that transports copper out of cells. This gene is located on chromosome 13, and more than 800 different mutations have been identified. The condition follows an autosomal recessive inheritance pattern, meaning both parents must carry a mutation for a child to be affected.

The primary risk factor is having two parents who are carriers of ATP7B gene mutations. Consanguineous marriages (between blood relatives) increase the risk, as do certain ethnic backgrounds where carrier frequencies are higher, including populations from Sardinia, Eastern Europe, and some Middle Eastern countries. Environmental factors do not cause Wilson Disease, but high copper intake from contaminated water or certain foods may worsen symptoms in affected individuals.

Prevention

Currently, there is no known way to prevent Wilson Disease. However, early detection through genetic screening and carrier testing can help families make informed decisions. Genetic counseling is recommended for families with a history of Wilson Disease, and prenatal testing is available for at-risk pregnancies. Newborn screening programs exist in some countries and can identify affected infants before symptoms develop. Family screening is crucial when one member is diagnosed, as siblings have a 25% chance of being affected.

Complications

Without treatment, Wilson Disease is universally fatal. Hepatic complications include acute liver failure, cirrhosis, portal hypertension, and hepatocellular carcinoma. Neurological complications can progress to severe disability, including dystonia, parkinsonism, ataxia, and cognitive impairment that may become irreversible if treatment is delayed.

Psychiatric complications may include severe depression, psychosis, and behavioral problems that can significantly impact quality of life. Other complications include kidney dysfunction, heart problems, bone disease with fractures, joint problems, and reproductive issues. Hemolytic anemia can occur during acute copper toxicity episodes. Early treatment can prevent most complications, but neurological and psychiatric symptoms may be only partially reversible once established.

Diagnosis

Diagnosis requires a combination of clinical, biochemical, and genetic testing. Initial screening includes serum ceruloplasmin levels (typically low in Wilson Disease), 24-hour urine copper excretion (elevated), and serum copper levels. An ophthalmological examination to detect Kayser-Fleischer rings using slit-lamp microscopy is essential.

Liver biopsy with quantitative copper measurement remains the gold standard for diagnosis, with copper levels typically exceeding 250 micrograms per gram of dry liver weight. Genetic testing for ATP7B mutations provides definitive diagnosis and is increasingly used as a first-line test. Brain MRI may show characteristic changes in the basal ganglia and brainstem in patients with neurological symptoms. Additional tests may include liver function tests, complete blood count, and assessment of kidney function.

Treatment

Treatment focuses on reducing copper accumulation and preventing further damage. First-line treatments include penicillamine, a chelating agent that removes copper from tissues, and trientine, an alternative chelator with fewer side effects. Zinc acetate or sulfate acts by blocking copper absorption in the intestines and is often used for maintenance therapy or in asymptomatic patients.

Tetrathiomolybdate is a newer agent particularly useful for patients with neurological symptoms, as it may cause less initial worsening. Liver transplantation may be necessary for patients with acute liver failure or end-stage liver disease who don’t respond to medical therapy.

Supportive treatments include management of specific symptoms such as tremor, psychiatric medications for mood disorders, and physical therapy for motor symptoms. Patients must maintain treatment lifelong, as discontinuation leads to copper reaccumulation and symptom recurrence.

Prognosis

With early diagnosis and appropriate treatment, patients with Wilson Disease can have a normal lifespan and good quality of life. The prognosis is excellent for asymptomatic patients who begin treatment before organ damage occurs. Hepatic symptoms generally respond well to treatment, with many patients experiencing complete recovery of liver function.

Neurological symptoms may improve more slowly, taking months to years, and some may be partially irreversible if treatment is delayed. Psychiatric symptoms often improve significantly with treatment. Without treatment, Wilson Disease is invariably fatal, usually within 2-3 years of symptom onset. The key to good outcomes is early detection and adherence to lifelong treatment.

Quality of life

Living with Wilson Disease requires lifelong commitment to treatment, but most patients can lead normal, productive lives. Dietary modifications include avoiding high-copper foods such as shellfish, nuts, chocolate, mushrooms, and organ meats, particularly during the first year of treatment. Patients should use copper-free water if their water supply is high in copper and avoid copper cookware and supplements containing copper.

Regular exercise is beneficial and generally well-tolerated once treatment is established. Patients should maintain regular sleep patterns and manage stress, as these can affect symptom control. Mental health support is important, as chronic illness and medication side effects can impact mood and psychological well-being.

Educational and workplace accommodations may be needed for cognitive or motor symptoms. Support groups and patient organizations provide valuable peer support and practical advice. Family education is crucial, as relatives need screening and may require genetic counseling.

Pregnancy and fertility

Wilson Disease can affect fertility in both men and women, causing menstrual irregularities, miscarriages, and reduced fertility. However, with proper treatment, fertility typically normalizes. Pregnancy is possible and generally safe for women with Wilson Disease who are on stable treatment.

Treatment adjustments may be necessary during pregnancy. Zinc is considered the safest option during pregnancy, while penicillamine and trientine require careful monitoring but can be continued if necessary. Copper levels should be monitored throughout pregnancy, and dose adjustments may be needed.

Genetic counseling is essential for affected individuals planning families, as each child has a 25% chance of being a carrier and needs carrier testing. Prenatal diagnosis is available if both parents are known to carry mutations.

Children

Wilson Disease in children often presents initially with liver symptoms, though neurological and psychiatric symptoms can also occur. Growth and development are usually normal with early treatment, but delayed diagnosis can impact both physical and cognitive development.

School accommodations may be needed for children with neurological symptoms affecting fine motor skills, attention, or learning. Regular monitoring is essential, as treatment needs may change during growth periods. Adolescence can be particularly challenging due to compliance issues with lifelong medication and dietary restrictions.

Transition to adult care should be carefully planned, with emphasis on the importance of treatment adherence. Family screening is crucial when a child is diagnosed, as parents and siblings require evaluation.

When to see a doctor

Seek immediate medical attention for signs of acute liver failure including yellowing of skin or eyes, severe abdominal pain, confusion, excessive fatigue, or vomiting blood. Urgent evaluation is needed for new neurological symptoms such as tremors, difficulty speaking or swallowing, coordination problems, or significant personality changes.

Routine medical care should be sought for unexplained fatigue, abdominal discomfort, mood changes, or any symptoms suggestive of liver disease in young people. Family members of diagnosed patients should seek evaluation for screening. Regular follow-up with specialists is essential for all diagnosed patients to monitor treatment response and adjust therapy as needed.

Regional context

Limited data exist specifically for Wilson Disease prevalence in the Caucasus region (Georgia, Armenia, Azerbaijan) or Eastern Mediterranean. Some studies suggest higher carrier frequencies in certain Middle Eastern populations, but comprehensive regional data are lacking. Healthcare infrastructure in these regions may present challenges for specialized diagnostic testing and treatment access.

GMJ welcomes contributions from regional researchers to build the evidence base for Wilson Disease in the Caucasus and to better understand regional genetic variants and treatment outcomes.

Research and clinical trials

Current research focuses on developing new copper-chelating agents, gene therapy approaches, and improved diagnostic methods. Studies are investigating the use of liver-directed gene therapy to restore ATP7B function and novel chelators with improved safety profiles.

Research is also examining biomarkers for monitoring treatment response and disease progression. Clinical trials are exploring combination therapies and personalized treatment approaches based on genetic mutations. Patients and families can search for relevant clinical trials at ClinicalTrials.gov and should discuss participation with their healthcare providers.

Frequently asked questions

Is Wilson Disease curable?

While Wilson Disease is not curable, it is highly treatable with lifelong medication. Early treatment can prevent complications and allow patients to live normal lives.

Will I pass Wilson Disease to my children?

If you have Wilson Disease, each child has a 50% chance of being a carrier and will only be affected if your partner is also a carrier (1 in 90-150 chance). Genetic counseling can provide personalized risk assessment.

Can I live normally with Wilson Disease?

Yes, with proper treatment and dietary modifications, most people with Wilson Disease can work, attend school, exercise, and participate in normal activities.

How often do I need monitoring?

Initially, monitoring may be needed every few months to adjust treatment. Once stable, annual or biannual check-ups are typically sufficient, including blood tests and clinical evaluation.

What happens if I stop taking my medication?

Stopping medication allows copper to reaccumulate rapidly, leading to symptom return and potentially life-threatening complications within months. Treatment must continue lifelong.

Support and resources

– Wilson Disease Association International (wilsonsdisease.org)
– Wilson’s Disease Support Group UK (wilsonsdisease.org.uk)
– Orphanet (orpha.net) – ORPHA:905
– National Organization for Rare Disorders (NORD) (rarediseases.org)
– EURORDIS (eurordis.org)
– International Copper Association (copperassociation.org)
– Global Liver Institute (globalliver.org)

Related conditions

– Hereditary Hemochromatosis – Iron overload disorder with similar organ damage patterns
– Alpha-1 Antitrypsin Deficiency – Genetic liver disease causing cirrhosis in children and adults
– Autoimmune Hepatitis – Can mimic Wilson Disease presentation in young patients
– Menkes Disease – Another copper transport disorder with opposite effect (copper deficiency)
– Primary Sclerosing Cholangitis – Progressive liver disease that may require similar monitoring

Sources: Orphanet (orpha.net), OMIM, GeneReviews (NCBI), WHO ICD-11, UpToDate, relevant EULAR/ACR/WHO guidelines. This article is for informational purposes only and does not constitute medical advice. Content licensed under CC BY 4.0.

Licensed under CC BY 4.0. Free to share with attribution to GMJ News.

Sources: Orphanet (orpha.net), OMIM, GeneReviews (NCBI), WHO ICD-11, EULAR/ACR guidelines. Schema.org MedicalCondition structured data included.